The United States International Trade Commission (ITC) decided to institute an investigation into unlawful acts against Hugel, Inc., Hugel America, Inc., and Croma Pharma GmbH
- A Medytox official stated that “the ITC investigation will reveal every detail of Hugel’s unlawful acts.”
- Medytox retained the global law firm Quinn Emanuel Urquhart & Sullivan, LLP (Quinn Emanuel) and secured the litigation fund from an investment firm specialized in litigation and dispute resolution.
On May 3rd, Medytox, Inc. (CEO, HyunHo Jung) announced that on May 2nd (local time) the ITC decided to institute an official investigation against Hugel, Inc., Hugel America, Inc., and Croma Pharma GmbH (Hugel) for the alleged theft and conversion of Medytox’s C. botulinum strain and misappropriation of related trade secrets.
A Medytox official stated that “The ITC’s decision of institution will reveal all details of unlawful acts by Hugel,” and “this ITC action will not only protect Medytox’s intellectual property rights, but will also serve as a momentum to redress the chronic problems of technology thefts which have been prevalent in the K-Bio industry.”
Medytox is represented in this action by the global law firm Quinn Emanuel, and also Medytox has secured litigation funding from a global leader in litigation and dispute resolution investments.